Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2(i)		
A, part 2(ii)		
A, part 2(iii)		
B (i)		
B(ii)	X	
C		
D		
E		X
F		X
G		X

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: **March 30, 2007**

State Party to the Convention: **Czech Republic**

Form A, part 1

Exchange of data on research centres and laboratories [1] - # 1

1. **Name(s) of facility** [2]
   Microbiological Laboratory BSL-3

2. **Responsible public or private organization or company**
   Veterinary Research Institute

3. **Location and postal address**
   Hudcova 70, 621 32 Brno, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (1 unit; total area approx. 100 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Microbiological laboratory BSL 3 is designed and provided for work with Risk Group 3 microorganisms and with large volumes or high concentrations of Risk Group 2 microorganisms that pose an increased risk of aerosol spread.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual or equivalent

Exchange of data on research centres and laboratories [1] - # 2

1. **Name(s) of facility** [2]
   Institute of Molecular Pathology (IMP)

2. **Responsible public or private organization or company**
   University of Defence (the Ministry of Defence)

3. **Location and postal address**
   Institute of Molecular Pathology, Faculty of Military Health Sciences
   Trebesská 1575, 500 01 Hradec Kralove

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Projects Protilatky 2 (Research of construction possibilities for a laboratory samples of a detector for the CWA and BWA using imunosensors and relevant mononuclear agents and development of designed laboratory samples), BojAgens (Virulent factors of *Francisella tularensis*; host-pathogen interaction) and Daldet III (System purposed for stand-off detection and identification of the CBA to timely warn the units against a chemical or biological attack)

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

   Cultivation of microbes for proteomic studies.
   Cultivation of microbes for *in vivo* infection intended for the study of tularemia.
   Cultivation of microbes for *in vitro* infection intended for study of microbe – host cells interaction.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defense research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
Institute of Molecular Pathology, FMMS, MoD, Hradec Kralove

2. Where is it located (include both address and geographical location)?
Trebesska 1575, 500 01 Hradec Kralove, Czech rep.

3. Floor area of laboratory areas by containment level:

BL2 20 (sqM)

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 180 (sqM)

4. The organizational structure of each facility.

(I) Total number of personnel 13

(ii) Division of personnel:

Military	2
Civilian	11

(iii) Division of personnel by category:

Scientists	10
Engineers	0
Technicians	2
Administration and support staff	1

(iv) List the scientific disciplines represented in the scientific/ engineering staff.
cell biology, molecular biology

(v) Are contractor staff working in the facility? If so, provide an approximate number.
NO

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?
Projects Protilatky 2, BojAgens (Virulent factors of Francisella tularensis) and Daldet III (Long distance detection of bioaerosols)

(vii) What are the funding levels for the following programme areas:

Research	YES
Development	-
Test and evaluation	-

(viii) Briefly describe the publication policy of the facility:

Results are published in international and national scientific and military journals.

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

Andersson H., Hartmanova B., Back E., Eliasson H., Landfors M., Naslund L., Ryden P.: Transcriptional profiling of the peripheral blood response during tularemia. *Genes and Immunity*, 2006, Vol. 7, pp 1-11.

Andersson H., Hartmanova B., Kuolee R., Ryden P., Conlan W., CHen W., Sjostedt A.: Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. *Journal of Medical Microbiology*, 2006, Vol. 55, Iss. 3, pp 263-271.

Hubalek M., Hernychova L., Brychta M., Lenco J., Zechovska J., Stulik J.: Comparative proteomic analysis of cellular proteins extracted from highly virulent Francisella tularensis ssp. tularensis and less virulent F. tularensis ssp. holarctica and F. tularensis ssp. mediaasiatica. In *Proteomics of Microbial Pahtogens*. Iss. 1, Weinheim: WILEY, 2006, pp 249-265.

Pavkova I., Reichelova M., Larsson P., Hubalek M., Vackova J., Forsberg A., Stulik J.: Comparative proteome analysis of fractions enriched for membrane-associated proteins from Francisella tularensis subsp. tularensis and F. tularensis subsp. holarctica strains. *Journal of Proteome Research*, 2006, Vol. 11, Iss. 5, pp 3125-3134.

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

The study of virulent factors, proteomics and vaccine development of *Francisella tularensis*, the interaction of *F. tularensis* with eukaryotic cells, the study of bioaerosols carrying of *Bacillus subtilis*.

*Including viruses and prions.

Exchange of data on research centres and laboratories [1] - # 3

1. **Name(s) of facility**[2]
   Central Military Health Institute, department Techonin

2. **Responsible public or private organization or company**
   Central Military Health Institute (Ministry of Defence)

3. **Location and postal address**
   Central Military Health Institute, department Techonin, 561 66 Techonin, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   wholly financed by the Ministry of Defence

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**

   BL 2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Cultivation of microbe (*Francisella tularensis*, vaccine strain LVS) for immunological studies, preparation of monoclonal antibodies and PCR probes

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

   detection of biological agents by special diagnostic techniques such as PCR, flow cytometry, biosensors and immunoassays

2. State the total funding for the programme and its source.
   wholly financed by the Ministry of Defence

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

   No

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
Central Military Health Institute, department Techonin

2. Where is it located (include both address and geographical location)?
Loc: 50°3'36.75"N; 16°36'39.81"E

3. Floor area of laboratory areas by containment level:

BL2 145 (sqM) [3 units BL 2]

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 145 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 15

(ii) Division of personnel:

Military	6
Civilian	9

(iii) Division of personnel by category:

Scientists	5
Engineers	0
Technicians	7
Administration and support staff	3

(iv) List the scientific disciplines represented in the scientific/ engineering staff.

general biology	(3)
clinical biology and chemistry	(1)
general zootechny	(1)

(v) Are contractor staff working in the facility? If so, provide an approximate number.
No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

Wholly financed by the Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research	1.000.000,-
Development	500.000,-
Test and evaluation	100.000,-

(viii) Briefly describe the publication policy of the facility:

Results are published in international and national scientific and military journals.

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

Immunological studies of model microorganism (Francisella tularensis, vaccine strain LVS) for detection of biological agents

*Including viruses and prions.

Exchange of data on research centres and laboratories[1] - # 4

1. **Name(s) of facility**[2]
   Laboratory for Biological Monitoring and Protection

2. **Responsible public or private organisation or company**
   National Institute for Nuclear, Chemical and Biological Protection, Department of Biological Protection

3. **Location and postal address**
   Pribram - Kamenna 71, 262 31 p. Milin

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is not financed by the Ministry of Defence.
   The Institute is a non-profit organisation established on the basis of the decision made by the chairperson of the State Office for Nuclear Safety.

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   BL – 4 (14 m^2)

6. **If no maximum containment unit, indicate highest level of protection**

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate are:**
   Detection of pathogens by molecular methods, microbiological cultivation, and mass spectrometry. Development, verification and evaluation methods for detection and quantification of biological agents and toxins and protection against them
   This laboratory is used for emergency response assistance for bioterrorism (initial triage and investigation of suspicious packages - primary identification and culture for *Bacillus anthracis*, etc.)
   (microorganisms: *Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Salmonella species, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psitaci, Coxiella burnetii, Rikettsia prowazekii*; toxins: Saxitoxin, Trichothecene toxins, Aflatoxins, Conotoxin, Tetrodotoxin, Microcystin).

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

Exchange of data on research centres and laboratories[1] - # 5

1. **Name(s) of facility**[2]
   Laboratory of Molecular Biology

2. **Responsible public or private organization or company**
   GENERI BIOTECH, s.r.o

3. **Location and postal address**
   Machkova 587, 500 11 Hradec Kralove

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is partly financed by the Ministry of Defence.

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate:**
   Multiplex system molecular detection of high-risky pathogenic microorganisms that might be used in field - project MOLECDETECTION (QRT PCR: *Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Salmonella species, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psitaci, Coxiella burnetii, Rikettsia prowazekii*)

Exchange of data on research centres and laboratories [1] - # 6

1. **Name(s) of facility** [2]
   Division of Infectious Diseases, Department of Infectious Diseases and Epizootology, Faculty uf Veterinary Medicine

2. **Responsible public or private organization or company**
   University of Veterinary and Pharmaceutical Sciences Brno (the Ministry of Education, Youth and Sports)

3. **Location and postal address**
   Palackého 1/3, 612 42 Brno

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   the Ministry of Education, Youth and Sports

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (total area approx. 40m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The laboratory provides research and diagnostic services (*Chlamydia psitaci*, Avian influenza viruses, Newcastle disease virus)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 7

1. **Name(s) of facility** [2]
   National Institute of Public Health; Centre of Epidemiology and Microbiology

2. **Responsible public or private organization or company**
   Ministry of Health of the Czech Republic

3. **Location and postal address**
   Srobarova 48, 100 42 Praha 10, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is wholly financed by the Ministry of Health

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 [3 boxes 7,3m^2 + 7,3m^2 + 10,05 m^2] total area approx. 107 m^2

8. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Diagnostic and public health laboratory
   Isolation and identification of *Mycobacterium tuberculosis* (human specimens)
   Revival and cultivation of strains of the Czech National Clollection of Type Cultures
   Cultivation of low-pathogenic strains of Avian influenza viruses
   Investigation of suspicious packages (identification and culture for *Bacillus anthracis*)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 8

1. **Name(s) of facility**[2]
   Bioveta, a.s.

2. **Responsible public or private organization or company**

3. **Location and postal address**
   Komenského 212, 683 23 Ivanovice na Hané, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Fully financed by own sources

5. **Number of maximum containment units**[4] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3

Name of laboratory	Area (m^2)
Quality control department	88
Bacterial products production department	134
Viral vaccines production department	80
Sterile pharmaceuticals production department	130
Lyophilisation department	138
Finalisation department	94

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Bacteria:
   production: cultivation for purposes of growing and production of the bacterial mass for further use (production of preparations, storage of the bacterial strains)
   use: activation of the stored freeze dried bacterial culture and cultivation
   procurement: purchasing of the needed bacterial strains from both Czech and foreign collections
   keeping: storage of the bacterial strains freeze-dried
   import: purchasing of the needed bacterial strains from foreign collections
   export: export of bacterial vaccines containing live vaccination strains
   transport: transport of bacterial vaccines containing live vaccination strains
   disposal: inactivation if this is a part of the technological procedure for production of the preparation
   inactivation for purposes of disposal (biological waste generated during the production process of the bacterial konzerv and preparations – control tests, growth properties, determination of the number of CFU etc.)

The following high risk biological agents are used for development, production and control of the veterinary immunopreparations (vaccines, diagnostics).

Bacillus anthracis
Brucella melitensis
Brucella abortus
Brucella ovis
Brucella suis
Burkholderia mallei
Burkholderia pseudomallei
Francisella tularensis
Salmonella typhi

Viruses:
production: cultivation for purposes of growing and production of the viral antigen for further use (production of preparations, storage of the viral strains)
use: activation of the stored viral strain (frozen, freeze dried…)
procurement: purchasing of the needed viral strains from both Czech and foreign collections
keeping: storage of the viral strains freeze-dried or frozen
import: purchasing of the needed viral strains from foreign collections
export: export of the viral vaccines containing live vaccination strains
transport: transport of the viral vaccines containing live vaccination strains
disposal: inactivation this is a part of the technological procedure for production of the preparation
inactivation for purposes of disposal (biological waste generated during cultivation – control tests, growth properties, determination of the titre etc.)
The following high risk biological agents are used for development, production and control of the veterinary immunopreparations.

Rabies virus
Aujeszky's disease virus
Avian influenza virus
Classical swine fever virus
Avian Newcastle disease virus
Teschen disease virus (porcine encephalomyelitis virus)

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 9

1. **Name(s) of facility** [2]
   State Veterinary Institute Prague

2. **Responsible public or private organization or company**
   public organization (Ministry of Agriculture)

3. **Location and postal address**
   Sidlistni 136/24, 165 03 Praha 6 – Lysolaje, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Financed by the Ministry of Agriculture

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   BL 4 Lab – FMD (area approx. 75 m^2)

6. **If no maximum containment unit, indicate highest level of protection**
   BSL 3 Lab – AI (area approx. 89 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Laboratory diagnostics – animal viruses and bacteria
   aflatoxins, trichotecens

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 10

1. **Name(s) of facility** [2]
   National Reference Laboratory for Anthrax

2. **Responsible public or private organization or company**
   State Veterinary Institute Hradec Kralove

3. **Location and postal address**
   Wonkova 343, 500 02 Hradec Kralove, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (1 unit; total area approx. 36 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Preservation and diagnostics of *Bacillus anthracis*.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual or equivalent

Background information on outbreaks of reportable infectious diseases #1 - human

Disease	Number of cases per year				
	2002	2003	2004	2005	2006
Listeriosis	20	12	16	15	83
Salmonellosis	2.256	1.822	1.788	1.034	1.272
Shigellosis	91	152	61	78	116
Viral Hepatitis A	30	26	0	163	22

Background information on outbreaks of reportable infectious diseases #2 - animals

Disease	Number of cases per year				
	2002	2003	2004	2005	2006
Rabies	3	0	0	1[+]	[0]

\+ 1 case of bat rabies

C. Encouragement of publication of results and promotion of use of knowledge

List of the most important publication which appeared during the year 2006:

Eyer L., Pantucek R., Zdrahal Z., Konecna H., Ruzickova V., Hernychova L., Preisler J., Doskar J.: Structural protein analysis of the polyvalent staphylococcal bacteriophage 812. *Proteomics*, 2006, Iss. 6, pp 64-72.

Ryden P., Andersson H., Landfors M., Naslund L., Hartmanova B., Noppa L., Sjostedt A.: Evaluation of microarray data normalization procedures using spike-in experiments. *BMC Bioinformatics*, 2006, Vol. 7, pp 1-17.

Sheshko V., Hejnova J., Rehakova Z., Sinkora J., Faldyna M., Alexa P., Felsbergg J., Nemcova R., Bomba A., Sebo P.: HlyA knock out yields a safer Escherichia coli A0 34/86 variant with unaffected colonization capacity in piglets. *FEMS Immunology and Medical Microbiology*, 2006, Vol. 48(2), pp 257-266.

Holy A.: Antiviral acyclic nucleoside phosphonates structure activity studies. Antiviral research Vol. 71, Iss. 2-3, pp 248-253

Tvrzova L., Schumann P., Sproer C., Sedlacek I., Pacova Z., Sedo O., Zdrahal Z., Steffen M., Lang E.: Pseudomonas moraviensis sp. Nov. And Pseudomonas vranovensis sp. Nov., soil bacteria isolated on nitroaromatic compounds, and emended description of *Pseudomonas asplenii*. International journal of systematic and evolutionary microbiology Vol. 56, Pt. 11, pp 2657-2663

Zeisbergerova M., Kostal V., Sramkova M., Babica P., Blaha L., Glatz Z.,Kahle V.: Separation of microcystins by capillary electrochromatography in monolithic columns. Journal of chromatography. B, Analytical technologies in the biomedical and live sciences Vol. 841, Iss. 1-2, pp 140-144

Horka M, Ruzicka F., Horky J., Hola V., Slais K.: Capillary isoelectric focusing of proteins and microorganisms in dynamically modified silica with UV detection. Journal of chromatography. B, Analytical technologies in the biomedical and live sciences Vol. 841, Iss. 1-2, pp 152-159

Zabka M., Drastichova K., Jegorov A., Soukupova J., Nedbal L.: Direct evidence of plant-pathogenic activity of fungal metabolites of *Trichothecium roseum* on apple. Mycopathologia Vol. 162, Iss. 1, pp 65-68

Lipoldova M., Demant P.: Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nature reviews. Genetics Vol. 7, Iss. 4, pp 294-305

Trebichavsky I., Splichalova A., Rychlik I., Hojna H., Muneta Y., Splichal I.: Attenuated aroA *Salmonella enterica* serovar Typhimurium does not induce inflammatory response and early protection of gnotobiotic pigs against parental virulent LT2 strain. Vaccine Vol. 24, Iss. 20, pp 4285-4289

Hassan M., Myrta A., Polak J.: Simultaneous detection and identification of four pome fruit viruses by RT-PCR. Journal of virological methods, Vol. 133, Iss. 2, pp 124-129

Hussein H., Habustova O., Turanli F., Sehnal F.: Potato expressing beetle-specific Bacillus thuringiensis Cry3Aa toxin reduces performance of a moth. Journal of chemical ecology Vol. 32, Iss. 1, pp 1-13

Krejci E., Kroppenstedt R.: Differentiation of species combined into the *Burkholderia cepacia* complex and related taxa on the basis of their fatty acid patterns. Journal of clinical microbiology, Vol. 44 Iss. 3, pp 1159-1164

Literak I., Smid B., Dubska L., Bryndza L., Valicek L.: An outbreak of the polyomavirus infection in budgerigars and cockatiels in Slovakia, including a genome analysis of an avian polyomaviruses isolate. Avian diseases Vol. 50, Iss. 1, pp 120-123

NovakovaD., Sedlacek I., Pantucek R., Stetina V., Svec P., Petras P.: *Staphylococcus equorum* and *Staphylococcus succinus* isolated from human. Journal of medical microbiology Vol. 55, Iss. Pt 5, pp 523-528

Liebl D., Difato F., Hornikova L., Mannova P., Stokrova J., Frostova J.: Mouse polyomavirus enters early endosomes, requires their acidic pH for productive infection, and meets transferrin cargo in Rab11-positive endosomes. Journal of virology Vol. 80, Iss. 9, pp 4610-4622

Basler M., Masin J., Osicka R., Sebo P.: Pore-forming and enzymatic activities of *Bordetella pertussis* adenylate cyclase toxin synergize in promoting lysis of monocytes. Infection and immunity Vol. 74, Iss. 4, pp 2207-2214

Yordanov M., Golkocheva E., Najdenski H.: Modulation of complement activity in vitro and in vivo by Yersinia wild and mutant strains. Folia microbiologica Vol. 51, Iss. 1, pp 27-32

Bialkova A., Subik J.: Biology of the pathogenic yeast *Candida glabrata*, Folia microbiologica Vol. 51, Iss. 1, pp 3-20

Tothova T., Pristas P., Javorsky P.: Mercuric reductase gene transfer from soil to rumen bacteria, Folia microbiologica Vol. 51, Iss. 4, pp 317-319

Matouch O., Vitásek J., Semerád Z., Malena M.: Elimination of Rabies in the Czech Republic. In: Dodet B., Schudel A., Pastoret P.P., Lombard M. : Rabies in Europe. Dev Biol (Basel). Basel, Karger, 2006, vol. 125, pp 141-143

McElhinney L.M., Marston D., Johnston N., Blafl C., Matouch O., Lalosevic D., Stankov S.,Must K., Smreczak M., Zmudzinski J.F., Botvinkin A., Aylan O., Vanek E., Cliquet F., Miller T., Fooks A.R.: Molecular Epidemiology of Rabies Viruses in Europe. In: Dodet B., Schudel A., Pastoret P.P., Lombard M. : Rabies in Europe. Dev Biol (Basel). Basel, Karger, 2006, vol. 125, pp 17- 28

Matouch O: Oral Immunization of Red Foxes Against Rabies in The Czech Republic.Abstract Book of the Ninth Annual Conference on Vaccine Research. Baltimore 2006, pp99

Form D

Active promotion of contacts

Planed international conferences, symposia, seminars and other similar forums for exchange

a) name of the conference, etc.
Analytical cytometry IV

arranging organization(s), etc.
Czech Association for Analytical Cytology

time June 23 – 26, 2007

place Hotel Myslivna, Brno

main subject(s) for the conference, etc.
Analytical cytometry

conditions for participation

point of contact for further information, registration, etc.
csac@ibp.cz ; www.csac.cz

b) name of the conference, etc.
XVI Conference of Young Microbiologists Tomasek Days

arranging organization(s), etc.
the Institute for Microbiology of the Faculty of Medicine of Masaryk University in Brno and St. Anna Faculty Hospital in Brno

time June 7–8, 2007

place Brno, Czech Republic

main subject(s) for the conference, etc.
general microbiology, factors of pathogenicity, epidemiology and epizootology

point of contact for further information, registration, etc.
tomdny@fnusa.cz

c) name of the conference, etc.
24th Congress of the Czechoslovak Society for Microbiology
Microorganisms at the threshold of the 21st century

arranging organization(s), etc.
Czechoslovak Society for Microbiology

time October 2 – 5, 2007,

place Liberec, Congress centre Babylon

main subject(s) for the conference, etc.
general microbiology, physiology of microorganisms, immunology, virology, bioinformatics, current and pending infections, bioremediation, biotransformation, diagnostics of microorganisms, medical and veterinary microbiology, culture collections

conditions for participation
open registration; registration fee (3200 CZK)

point of contact for further information, registration, etc.
www.biologicals.cz/cssm/ ; gabriel@biomed.cas.cz

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulation	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other microbiological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES/[redacted]	YES/[redacted]	[redacted]/NO	[redacted]/NO
(b) Exports of micro-organisms* and toxins	YES/[redacted]	YES/[redacted]	[redacted]/NO	[redacted]/NO
(c) Imports of micro-organisms* and toxins	YES/[redacted]	YES/[redacted]	[redacted]/NO	[redacted]/NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention

Declaration of vaccine production facility - #1

1. **Name of facility:**

   Baxter BioScience s.r.o.

2. **Location (mailing address):**

   Jevany-Bohumil 138, 281 63 Kostelec nad Černými lesy

3. **General description of the types of diseases covered:**

   list of products manufactured: Influenza vaccine/s (whole virion) against flu (human); Cell culture preparation, cultivation of influenza viruses, harvest, inactivation, purification, transfer to facility in Austria for final filling

   list of products manufactured and distributed: none

   list of products on which R&D is carried out: none

   list of products distributed: none

Declaration of vaccine production facility - # 2

1. **Name of facility:**

   Sevapharma a.s.

2. **Location (mailing address):**

   Korunní 108, 101 03 Praha 10, Czech Republic

3. **General description of the types of diseases covered:**

   Production of vaccines, immunomodulators, allergens and diagnostics (microbial, viral, immunochemical and other).

viral vaccines:	live vaccine against measles, mumps and rubella
bacterial vaccines:	vaccine against tetanus multi-component staphylococcus toxoid anti-staphylococcus phage lyzate for topical application

Declaration of vaccine production facility- # 3

1. **Name of facility:**

   Bioveta, a.s.

2. **Location (mailing address):**

   Komenského 212, 683 23 Ivanovice na Hané, Czech Republic

3. **General description of the types of diseases covered:**

   Manufacturer of: veterinary vaccines for use in animals
   in vitro diagnostic test kits for diagnosis of animal diseases
   diagnostic antigens
   positive diagnostic sera
   antisera and globulins for use in animals

Production of veterinary vaccines:

Bacterial

Vaccine against anthrax, Inactivated vaccine against Lyme disease, Inactivated vaccine against canine and fur animal leptospirosis, Inactivated vaccine against mycotic disease caused by Microsporum canis in dogs, Vaccine against tetanus, Live vaccine against red murrain in pigs, Inactivated vaccine against porcine erysipelas, Vaccine against enteric coli infections in suckling piglets and against porcine erysipelas, inactivated, Vaccine against enteric coli-infections of suckling piglets, Vaccine against leptospirosis in cattle and horses, Vaccine against bovine infectious keratoconjunctivitis, inactivated, Rabbit pasteurellosis vaccine inactivated, Vaccine against porcine pleuropneumonia, Pig rhinitis vaccine with dermonecrotoxical toxoid, Vaccine against salmonellosis in poultry, attenuated, Avirulent vaccine against bovine trichophytosis, Lyophilized vaccine against bovine trichophytosis, Vaccine against horse trichophytosis, Vaccine against trichophytosis in animals with fur

Viral

Inactivated vaccine against coronary viral disease in dogs, Live vaccine against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirosis and parainfluenza in dogs, Live vaccine against distemper and parvovirosis in dogs, Live vaccine against parvovirosis in dogs, Vaccine against rabies, inactivated, Vaccine against panleucopenia, calicivirus and herpesvirus infection of cats, The vaccine against feline panleukopenia, herpesviral and caliciviral infection, and rabies of cats, Inactivated vaccine against equine influenza, Vaccine against IBR inactivated, Vaccine against rabies intended for oral immunization in foxes, Live vaccine against myxomatosis, MXT, Live vaccine against infectious bronchitis in poultry, lyophilised, Live vaccine against infectious bursitis in poutry (Gumboro disease), lyophilized, Duck infectious hepatitis inactivated vaccine, Vaccine against Parvovirus Disease in Goslings, Inactivated, Live vaccine against Newcastle disease in poultry, lyophilized, Inactivated vaccine against the egg drop syndrome, Inactivated vaccine against Newcastle disease and infectious bursitis in poultry, Vaccine against

porcine parvovirosis, inactivated, Vaccine against swine fever TVM-1, Vaccine against pest in rabbits, Vaccine against pest and myxomatosis in rabbits,

Combined (bacterial and viral)
Vaccine against canine distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus, parainfluenza and leptospirosis in dogs and furry animals, Vaccine against canine distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus, parainfluenza, leptospirosis and rabies in dogs and furry animals, Inactivated vaccine against canine and fur animal leptospirosis and rabies, Live vaccine against red murrain and pest in pigs, Inactivated vaccine against equine influenza and tetanus, Vaccine against rota, corona and coli infections in newborn calves, inactivated, Vaccine against parvovirosis and swine erysipelas, Vaccine against rotaviral and enteral coliinfections in pigs

Diagnostic test kits
Kit for diagnostics of leucosis in cattle by immunodiffusion test, Set for serological diagnostics of brucellosis using the slow agglutination, Set for serological diagnostics of brucellosis using the quick agglutination, Set for diagnostics of brucellosis – RBT, Set for diagnostics of brucellosis using the complement bond reaction (CBR), Set for diagnostics of dourine using the complement bond reaction (CBR), Set for diagnostics of chlamydiosis using the complement bond reaction (CBR), Set for diagnostics of listeriosis by slow and quick agglutinations, Kit for diagnostics of paratuberculosis using the complement bond reaction (CBR), Set for diagnostics of pullorosis using the slow agglutination, Set for diagnostics of pullorosis using the quick agglutination, Set for diagnostics of anthrax using by precipitation method, Set for diagnostics of tularemia, Set for diagnostics of glanders using the complement bond reaction (CBR),

Declaration of vaccine production facility - #4

1. **Name of facility:**

   Dyntec, s.r.o.

2. **Location (mailing address):**

   Pražská 328, 411 55 Terezín, Czech Republic

3. **General description of the types of diseases covered:**

   Human vaccine: per-oral vaccine against bacterial diarrhoea

   Veterinary products:
   - vaccines against *Actinobacillus pleuropneumoniae* and edema disease of pigs
   - vaccines against parvovirosis and erysipelas of pigs
   - vaccines against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirosis, parainfluenza and leptospira icterohaemorrhagiae, grippotyphosa and sejroe of dogs
   - vaccine for the prevention of rabies in wild carnivorous animals and stray dogs
   - vaccines against myxomatosis and viral hemorrhagic disease of rabbits

Form G

Declaration of vaccine production facility - #5

1. **Name of facility:**
   BIOPHARM, Research Institute of Biopharmacy and Veterinary Drugs

2. **Location (mailing address):**
   Pohori-Chotun, 254 49 Jilove u Prahy

3. **General description of the types of diseases covered:**
   Vaccine against coccidiosis in poultry